StreetsTalksto podcast

Challenging Thinking. Shaping Debates. Influencing Outcomes.

StreetsTalksTo The Derivatives Service Bureau (DSB)

Published April 2026

In this episode, Julia Streets sits down with Emma Kalliomaki to explore the critical role of the Derivatives Service Bureau (DSB) as the “golden source” of reference data for the over-the-counter (OTC) derivatives market. As the industry transitions from rapid regulatory implementation to a “steady state,” Emma discusses how standardised identifiers (OTC ISIN, UPI, CFI) and global collaboration continue to drive market transparency and reduce operational and regulatory burden for its 1,900+ users worldwide.

Key Highlights

  • Evolution from Implementation to Stabilisation: After eight years of operation and following the successful global rollout of the Unique Product Identifier (UPI) into the Identifier framework for OTC Derivatives over the last couple of years, the DSB’s user base has expanded from regulators and reporting firms to a much broader community. The DSB is therefore transitioning to a discovery-led approach focussed on deepening their understanding of how their data is accessed, used and integrated across an increasingly diverse ecosystem 
  • Commitment to Fair Cost Allocation and Transparency: As a market utility,  with a  user base expanding to include a vast network of indirect and non-fee-paying entities, the DSB remains committed to its core principle of fair allocation of cost

The episode emphasises the importance of the Annual Industry Consultation, calling for diverse stakeholders, from boutique buy-side firms to global sell-side institutions, to provide feedback on DSB service evolution and the equitable distribution of costs.

Emma Kalliomaki, Managing Director for DSB and ANNA

Emma Kalliomaki is Managing Director of the Derivatives Service Bureau (DSB). She is also Managing Director of the Association of National Numbering Agencies (ANNA). Emma has over a decade of experience in financial data, standards and regulation, previously also working as head of the London Stock Exchange’s SEDOL Masterfile.

Transcript

Julia Streets: Hello, my name is Julia Streets and welcome to the podcast series, StreetsTalksTo. In every episode, I interview leaders from some of the most influential firms, bodies, and initiatives in the financial services industry. We explore what’s at the very forefront of innovation and change, and we think about the challenges facing firms and the industry at large, as we uncover the opportunities that exist today and as we look ahead. Now, right now, every client, every firm is looking to achieve two key things: growth and/or transformation. And as a business, we help firms with three key offerings: campaigns, content, and coaching, because we never forget the humans in the mix. We hope you enjoy the series, which you can find on all good podcast channels. All the episodes are listed on our website, streetsconsulting.com, and you can find the episodes using the hashtag #StreetsTalksTo.

Thank you for listening and welcome to StreetsTalksTo the Derivatives Service Bureau. Let me just tell you a little bit about DSB. The DSB (Derivatives Service Bureau) is committed to the use of international standards to make the OTC derivatives market a more stable and more efficient environment from which to trade. And it provides OTC derivatives descriptive reference data on a cost-recovery basis. So when you think about what that means, it’s all about enabling market participants to meet regulatory reporting obligations and underpinning the very foundations of industry efficiency and transparency, all through the consistent development of an interoperable OTC derivatives identifier framework. So when you think about it, the DSB is the golden source of reference data for the OTC derivatives industry, serving more than 1900 organisations spanning 40 jurisdictions. So think ISINs, UPIs, CFIs, FISN identifiers for OTC derivatives market, the sole generator committed to the development of OTC derivatives identifiers.

So, having set that scene, I am so delighted today because we’re joined by the Managing Director, Emma Kalliomaki. She’s also the Managing Director of the Association of National Numbering Agencies. So, Emma, welcome. When we think about industry representation, expertise, and collaboration, of course, is the word that everybody’s using. It really strikes me that these are core and foundational to everything that you’re doing. Can you give us a sense of why this is particularly important right now, and also what you’re focused on as you’re looking ahead?

Emma Kalliomaki: Sure. Well, thank you for having me, Julia. I really appreciate the opportunity to talk about the important work that the DSB is doing. And really, as an industry utility, collaboration is fundamental to the evolution of the service. We need to ensure that we are able to meet the needs of our stakeholders—so from a market participant point of view, they can meet their regulatory reporting obligations, and then from an authority standpoint, to ensure that they can undertake their necessary supervisory functions. Now, when we think about those two parties, we’ve got public and private sector coming together, and so that alignment, harmonisation, working together for a mutual benefit is really core to what we do.

Now, when the DSB went live in 2017 to launch the OTC ISIN service, there was a particular focus there on the EU, which at the time included the UK, and ensuring that meeting the needs of MiFID, so rolling out for transaction reporting, was kind of at the front of what firms were looking at. Now, knowing at that time that the Unique Product Identifier (UPI) was coming, following the financial crisis, knowing authorities wanted to ensure that they had a means for global aggregation of data to monitor systemic risk, we were able to consider that design model and ensure that the OTC ISIN evolved to cater for a future OTC derivatives identifier framework.

Now, we were able to demonstrate that and were successfully appointed as the UPI service provider, and after six years from going live with the OTC ISIN service, we then successfully launched the UPI service. So you can understand that transition we had from working with the EU and the UK to then needing to service the needs of G20 jurisdictions. Now, over the last three years, that collaborative effort has been key, trying to better understand the needs of the individual jurisdictions in the adoption and implementation of the UPI, whilst ensuring that we have, as it is an international standard, a common means of doing that.

So really the collaboration, looking at the different stakeholders, the broad and varied size and type of entities that we’re having to service, it’s really key that we keep engaged and that we have that understanding of the role of the DSB and how firms need to use us. So really the focus has been on the DSB ensuring that there is awareness and understanding of the role the DSB plays and engaging with firms of all different sizes and with the authorities in order to ensure that the services has continued to evolve to meet those needs. So the focus has really been on that adoption and implementation, now I would say going forward we are transitioning into a stable state. We need to have a deeper understanding of how firms are using our data, what workflows have been embedded, what has worked and what needs further refinement as we move forward. Collaboration will remain integral to the future evolution of the service.   

Julia Streets: And it’s wonderful to hear about the history as well as the changing dynamics, which we so often underestimate in terms of how, whether it’s regulatory changes or whether it’s jurisdictional changes, or indeed geographical line boundary changes in many ways, but also the changing requirements of the market. 

So let’s go a little bit further into that. When we talk about how you engage with the market participants, policy makers, the regulators that you’ve just talked about, how do you do that? Do you have particular processes and models that you follow?

Emma Kalliomaki: Yes we do. We have a governance framework which requires us to have industry representation groups that feed into the evolution of the service. So we have market participants, subject matter experts essentially in each of the areas for which we have a committee, that come together with regulatory observers who sit on those committees with the DSB. 

We have three committees: one that focuses on product-related matters, so that is more the technical content into the definitions of the identifiers that we service; then we have a Technology Advisory Committee, who is much more focused on our infrastructure, the architecture. As we know, technology moves fast, so it’s important to maintain pace with that level of change, and they also look at the workflows, so the integration and connectivity of the DSB and the end users. And then we have our Governance Advisory Committee, who focus much more on the business-related matters, so our terms and conditions, the user fees, and the approach, our fair allocation of cost, which is something that we’ve been looking at more recently.

But in addition to those industry representation groups that sit within the DSB’s governance framework, we also have monthly discussions with the Committee on Derivatives and other Identifiable Data Elements, which is under the Regulatory Oversight Committee, in order to ensure the authorities are comfortable with the approach the DSB is taking. We also participate in events and work with our partners who are third-party service providers, as an example, to ensure that we can participate in their client events, etc., to give them the information direct from the horse’s mouth, for lack of a better phrasing. In addition, I participate in committees that are hosted by the authorities, so ESMA’s committees on regulatory working group, as well as the Bank of England and FCA’s Data Committee, which helps us give information and feedback into those other industry forums as well.

So it’s quite important for us to have engagement on both sides as in with the authorities and with market participants and to ensure they’re brought into the DSB’s loop. And then we also have, on an annual basis, an industry consultation. Now, we appreciate that the industry representation groups only cater for a number of firms to be able to participate and give targeted feedback in those forums, but the annual industry consultation is an opportunity for the broad network of DSB users, both fee-paying and non-fee-paying, to contribute.

Just to put a bit of context there, the DSB, as you mentioned in your intro, the DSB has over 1900 entities connecting to the DSB, and we also have almost 600 fee-paying entities. So that’s quite a broad user base. We’re talking about small boutique firms, buy-side, sell-side, multi-jurisdictional, you know, global institutions, and we offer all different types of functionality. So it’s quite important from an annual industry consultation point of view to try and broaden the net to get engagement from that broad set of users in relation to the service evolution, so we ensure that the service meets the needs of the whole user base.

Julia Streets: And as you begin to break some of that down, I think what’s really fascinating is you talk about everything from the technical to the infrastructure, to the business case, to the regulatory point of view, to the high-level supervision governance point of view, and these very clear models of almost small group engagement, but also multilateral, global ways of engaging with your community, if we wanted to describe it that way. Can I pick up on one of those? You talk about regulators and your engagement with the regulators, and I can’t help but think that right now we’re just going through,I mean, there’s a lot going on, but particularly honing in on the dynamics of regulatory change. Love to hear your thoughts about what’s your community particularly focused on now, what do you think the regulators are focused on now?

Emma Kalliomaki: That is a fantastic question. It’s very topical for those involved in the industry would be very much aware of the consultations and the call for evidence that have come out since last year across the EU and the UK. So really there are some common themes looking at burden reduction, how to streamline reporting and to ensure that there are efficiencies that can be leveraged to remove duplication from firms and to ensure that the markets remain competitive. And really, standards and the role the DSB plays are integral to that when we think of the reference data that underpins regulatory reporting, the need to be able to uniquely and unambiguously identify the instruments within these transactions.

It is really paramount to have the appropriate data points and the data quality. So the standards and the role of the DSB, that collaboration that comes from stakeholders across public and private sector, really feed into positioning how we can use those standards to drive those aspects, especially when it comes to burden reduction, streamlining alignment, removing duplication. If you think of an identifier, it encapsulates quite a number of data points—I won’t get into the technical detail here—but really, the data points that are encapsulated within an identifier and the process in which they are assigned means that you have embedded normalisation, standardisation, validation into the attribute before the identifier is generated.

And when you transfer that into regulatory reporting, it means by using the identifier, you’ve then got that embedded data quality in that one data point. And so looking at ways of burden reduction, you could remove additional data elements that are already contained within the identifier wrapper, as we could say, and they are like low-hanging fruit aspects that could lead to burden reduction. Firms won’t have to report the same number of fields, and when you think of data quality and interpretation that’s gone into agreeing and normalising those fields, it’s quite key. 

At this point, we see the authorities in the EU and the UK really taking a step back. You know, we’ve had quite a period of regulatory change through implementation and rewrites, and now they’ve taken stock to think, okay, what can we do more holistically? I would say there’s been organic growth in regulatory change over the last 10 years, and now is the opportunity to say, okay, we’ve done all of this, objectives have been met, but what can we do now to ensure as we move forward we’re as streamlined, efficient, and harmonised as possible and ensuring that that burden reduction can be passed on to firms? So the role of the DSB as a golden source of data, as with other standardised data sets, I think plays an important role in achieving those objectives.

Julia Streets: It really feels like this is a moment where we’ve been through a journey of understanding data, getting some clarity around data, that transparency you describe, and now a very thoughtful chapter, if you like, to be able to think about what is that data going to do, what value does it bring to all of your constituents and participants, and also what do they need as they look ahead, which I think is really, really fascinating. Thank you for not getting too technical. I mean, it’s really fascinating, isn’t it, because it could be one of those conversations that could become very technical. But I do want to actually invite you to become a little technical, because I do want to talk about the OTC derivatives identification framework, because we know this is really key right now. And I would like to ask you about the current focus around that because I know there are some things that the industry’s really thinking about.

Emma Kalliomaki: The OTC derivative identifier framework is quite important as in the hierarchy that sits behind the different use cases for the standard. So we have the Classification of Financial Instruments (CFI) that sits at the top, it provides the common level of classification across the different products and instruments. Then you have the UPI (Unique Product Identifier), which gives us the product-level identification with the primary purpose of allowing authorities to aggregate on a global scale OTC derivative data that’s reported to trade repositories in order to monitor systemic risk. So that’s essentially the common baseline that the G20 jurisdictions agreed on that was needed for them to fulfill that systemic risk monitoring obligation.

And then you move down to the most granular identifier, which is the OTC ISIN, which is primarily used for transaction reporting in order to help the authorities detect market abuse, and it was also used for the transparency use case initially when it was rolled out. Now, the harmonisation and alignment between those identifiers is key. So you will have for any OTC ISIN a parent UPI, so you can understand the lineage and the data attributes needing to stay in sync is quite important. And that’s where looking at the standardization and the suite of standards is key from a DSB point of view, but also from an ISO point of view. So ISO, the International Organisation for Standardisation, is responsible for the development and maintenance of those standards.

And then you have what we refer to as registration authorities, who are responsible then for the adoption and implementation of the standard. And we have ANNA (Association of National Numbering Agencies), who I’m also Managing Director for, who is the parent company of the DSB, who is the registration authority for the ISIN standard and also coordinates the efforts of national numbering agencies for the implementation and adoption of not only the ISIN but also for the FISN, which is a descriptive identifier, and the CFI, as I already mentioned, Classification of Financial Instruments.

So this year we have quite an important milestone: both the ISIN and the CFI standards are moving into what is called a ballot for their systematic review. And that is every five years, a standard is put within the ISO framework for the members to vote as to whether a systematic review is needed. And that is like a revision of the standard. So whilst the OTC ISIN, given the complexity and evolving nature of OTC derivatives, the methodology for how ISINs are assigned is not embedded within the ISIN standard, that is passed through to the DSB and through its collaborative model to shape that methodology. The other aspects of the standard, other asset classes, are still very important to the DSB because, as we know, OTC derivatives are all based on other financial instruments.

So having a review and feeding into the review of the ISIN standard is still quite key for the DSB, looking at how referential instruments are assigned—talking about indices as one example, commodities as another example—but also the coverage of equities and debt, but also other emerging asset classes that need to be considered. So digital assets is a great example—already incorporated in the standard but definitely needs to be reflected in the hard copy and also considered from a DSB point of view as far as being used for under lyers. Other areas that have come up, carbon credits, you know, all good examples of the sustainable aspects that are being looked at. But I think the important part is that that evolution, the DSB will feed into that, both for CFI and the ISIN, and then later in the year, the UPI standard already is reaching its five-year milestone of that standard being put into place. So the DSB will once again be very involved in putting forward proposed amendments for how that standard will evolve.

Julia Streets: And it’s really fascinating listening to you speak because it’s a highly complex industry—OTC derivatives—as you mentioned, the very nature of every trade, every transaction, how it is formed, how it is traded, all the post-trade, highly interoperable, global industry that is going through incredible dynamics of change. And hearing you talk about the intricacies of every single dynamic of every single standard, its role, its application—you talked about market abuse, you talked about the need for transparency, we’ve talked earlier about burden reduction, the regulatory point of view as well—I’m getting a really clear sense of the importance of the DSB and its function. We talked about its history, where it is now, and then also its kind of view on the future as well.

I wonder if I could return to a comment you made earlier about the formal industry consultation that is taking place at the moment. Give us a sense of anything that is going to come out of that this year?

Emma Kalliomaki: Well, I think there are a couple of themes that we’ve been focusing on and that roll over from last year also. As I had mentioned, the UPI service we have adopted and implemented now in 11 jurisdictions. We’ve got another two jurisdictions who are on the radar for either this year or next year, but that is quite important in considering where the DSB has come from and where we’re moving to. So where we were in the phase of letting market participants know across the broad jurisdictions that we were touching upon what the role of the DSB is, how they interact with us, what their connectivity and functionality is available to them, we’re now moving into that steady state where we need to better understand how firms are using the data.

So what that means and also the stabilisation. So last year we already started looking at the fair allocation of cost, given now we have—there’s three times the number of fee-paying UPI users compared to ISIN users. So really this fair allocation of cost is something we started looking at last year, changing how the cost is allocated between the two services, but also looking at how we could broaden the contributions to cost recovery. So it’s worth noting that 75% of the DSB’s user base accesses the services for free, so accesses OTC derivative data, the DSB’s golden source of reference data for free. So what can we do to ensure that there’s proportionality and to ensure that we have a deeper understanding of the full network, the ecosystem that is utilising DSB’s data?

And what we came to learn last year through the implementation of a new user type—the distributor user—was that actually the boundary extends far beyond where the touch point with the DSB is. So the number of indirect users is beyond what we had visibility of, and that’s one of the areas that we’ll get more insights into as we move forward with further exploration on this fair allocation of cost. 

Also when we think of burden reduction, one of the roles the DSB can play in this is understanding that firms have competing priorities, looking at regulatory change, also trying to bring cost efficiencies and streamline, come to terms and standardise their own regulatory reporting workflows and inputs, trying to understand better their own workflows and the data inputs that are required. 

What can the DSB do? You know, we can minimise the amount of change that’s required on our side and focus on the steady state, looking at aspects like data quality. We’ve had the implementation phase of the UPI, which is really taking the theory, the UPI standard, and putting it into practice. Now we have the benefit of two years of use, utilisation, and that means we have data to help drive analysis for how we move forward. What are the aspects from a data quality point of view that need to be assessed? Is the UPI data able to service the needs of the supervisory authorities as was expected, as was anticipated? So the ongoing dialogue around those points is really important. So we see those as being key aspects for how we move forward. And then that broader utilisation. 

I’ve talked about us being in a discovery mode now wanting to better understand the downstream data flows, who are the members of the ecosystem, and really we have had little exposure to that full range of the ecosystem, so we really want to deepen our understanding and discovery of that ecosystem.

Julia Streets: And as we close out our discussion today, I mean, it feels like there’s a definite call to action to engage. What would be your message to the global OTC derivatives community about partly why this matters, but what they need to do?

Emma Kalliomaki: The annual industry consultation is the mechanism for us to receive responses, to receive feedback in the most transparent way possible. So all market participants are able to see what views are coming in from the different sectors. Now, that feedback can also be provided anonymously, and it also can be provided on just parts of the consultation, not necessarily the full consultation if you don’t believe all aspects are relevant to you. But what is important is that we hear from the voices of the varying participants within the market—firms of all different sizes from different aspects of the ecosystem in order to drive the evolution of the service.

Now, if we don’t hear from the broad range of voices, then it makes it very difficult for us to make change that would align with the expectations of those participants. So whether you’re fee-paying or non-fee-paying, it’s also important, and we want it from all the different jurisdictions. Now, whilst they are international standards, we do see that there are divergent interpretations or approaches, and they need to be also brought together to the table. So it’s important for every voice, no matter how small you think your comment is, it is still valuable to us and we strongly recommend for all feedback to come. 

We’re also trying to complement that with bilateral outreach. So we understand that time is of a premium, as I’d mentioned, competing priorities, it’s always tough. So we are also reaching out to firms and asking firms to reach out to us if you want to have a bilateral dialogue for us to capture your thoughts and views and to also be used as a sounding board for some of the aspects that might be coming up in other conversations that we can get broader and more holistic feedback on.

Julia Streets: So it’s definitely a clarion call for the industry: now’s the time, now’s the time absolutely to get involved. As you say, if elements of that consultation you don’t feel apply to you, doesn’t matter, there are sections you can do, get in touch, be bilateral, but also make sure we hear the voices of everybody, because otherwise the risks, of course, is the decisions that are made and the pathways that follow don’t represent the interest of all. 

What’s fascinating as I kind of reflect on our whole discussion is, you know, there are some really key things coming through—whether that’s about fair cost allocation, whether it’s about burden reduction, data quality, utilisation, regulation—that these are all topics that matter to everybody. So it feels like I’ve caught you at a very good time where you’re really in this phase of discovery. So if anybody wants to find out more about the DSB, you can go to the website at anna-dsb.com, or you can also follow the Derivatives Service Bureau on LinkedIn. That’s probably the best way to get in touch. And to all our listeners, first of all, thank you for listening as always. I hope you’ve enjoyed this conversation with Emma Kalliomaki. Emma, thank you again for taking the time.

Emma Kalliomaki: Thank you, I really appreciate it.

Julia Streets: You’re always welcome, always welcome, it’s always a joy to see you. And to everybody who’s been listening, thank you very much, until next time, goodbye!

This episode of StreetsTalksTo was produced by PodShop on behalf of Streets Consulting Limited. At Streets Consulting, we are a strategic business development, marketing, and communications consultancy focused on helping financial services and technology clients around the world. Every client is focused on growth and transformation, and as fintech PR specialists, we are there to help them every step of the way. We do this through our three Cs: campaigns, content, and coaching, because we never forget the human in the middle. 

You can find this episode on streetsconsulting.com and using the hashtag #StreetsTalksTo. And we can also be found on LinkedIn and on YouTube. Thanks for listening!